Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement in patients with isotonic dehydration,Maintenance of hydration and electrolyte balance when oral intake is inadequate,Vehicle for intravenous administration of compatible drugs,Hypovolemia (off-label),Shock (off-label)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Glucose has a plasma half-life of approximately 1.5-2.5 hours in normal individuals, reflecting rapid cellular uptake and metabolism. Sodium and chloride have no definable half-life as they are actively regulated; however, the half-life of infused sodium is approximately 2-4 hours depending on renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the Krebs cycle to carbon dioxide and water; insulin-dependent. Sodium chloride is not metabolized; excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Glucose is completely metabolized to CO2 and water; renal excretion of unchanged glucose is negligible (<1%) in normoglycemic patients. Sodium and chloride are primarily excreted renally (90-95% of infused load) with small fecal and sweat losses. In dextrose 5% and sodium chloride 0.9%, both components are eliminated renally; the dextrose is metabolized, not excreted unchanged.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible (<1%) binding to plasma proteins. Sodium: not protein-bound. Chloride: not protein-bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: Vd approximately 0.15-0.25 L/kg (primarily extracellular fluid). Sodium and chloride: Vd approximately 0.25 L/kg (distributes into extracellular space). Total body water distribution occurs only if free water is present.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% bioavailability. Not administered orally for these purposes; if ingested, dextrose undergoes first-pass metabolism (oral bioavailability ~50-60% due to hepatic extraction) and sodium chloride is fully absorbed.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Not applicable; contains sodium chloride and dextrose; monitor serum sodium and glucose in renal impairment. For GFR <30 m L/min, use with caution due to risk of hypernatremia and fluid overload.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment; monitor blood glucose in hepatic impairment due to risk of hyperglycemia.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion; dose based on fluid and electrolyte needs, typically 5-10 m L/kg per hour, adjusted for clinical response; maximum rate 20 m L/kg/h in neonates.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution; lower infusion rates recommended due to reduced renal function and higher risk of fluid overload and electrolyte disturbances; monitor serum sodium and glucose closely.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA black box warnings.
None.
Hyperglycemia in patients with diabetes or stress-induced hyperglycemia,Fluid overload in patients with heart failure, renal impairment, or edematous states,Hyponatremia (especially in children, elderly, and post-operative patients),Hypernatremia with excessive administration,Osmotic demyelination syndrome with rapid correction of hyponatremia,Phlebitis or extravasation at infusion site
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia (severe) when dextrose use is inadvisable,Hypernatremia,Acute intracranial hemorrhage (if using hypotonic solutions, but not applicable here),Severe renal impairment (oliguria/anuria) with volume overload risk,Patients with known hypersensitivity to dextrose or corn-based products
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions. However, monitor total sodium and glucose intake if patient is on a restricted diet for diabetes or hypertension.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No trimester-specific risks.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Exogenous dextrose and sodium chloride are normal blood constituents; negligible transfer into milk. M/P ratio not applicable. Compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustments for dextrose 5% and sodium chloride 0.9%; use standard dosing. Monitor for gestational hyperglycemia and edema; adjust rate based on clinical status.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Must confirm IV access patency before infusion; hypertonic 0.9% Na Cl may cause phlebitis. Use with caution in heart failure, renal impairment, or hypernatremia. Monitor serum glucose and sodium levels during prolonged administration. Not suitable for dilution of incompatible medications.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inform your doctor if you have heart disease, kidney problems, or high blood pressure.,Report any signs of allergic reaction (rash, itching, swelling) or infusion site pain/redness.,This solution provides sugar and salt; your fluid and electrolyte levels will be monitored.,Do not stop or adjust the infusion rate without medical advice.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is a Electrolyte that works by Dextrose 5% provides a source of calories and fluid for hydration, preventing ketosis by providing a minimal carbohydrate source. Sodium chloride 0.9% supplies electrolytes and maintains osmotic pressure in extracellular fluid.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is: Intravenous infusion; typical adult dose is 500-1000 m L as a single dose, administered at a rate determined by clinical condition (e.g., 100-200 m L/h for maintenance).. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk at standard doses. Excessive sodium may cause maternal hypernatremia with fetal effects indirectly. No . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.